SHOX2 and non-small cell lung carcinoma: In our study cohort, lung cancer (nonsmall-cell lung cancer, NSCLC and small cell lung cancer, SCLC) accounted for the largest proportion of MPE, and the sensitivity of SHOX2, RASSF1A, and TM were 91.1% (41/45), 64.4% (29/45), and 97.8% (44/45), respectively.